Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study.
Saved in:
| Title: | Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study. |
|---|---|
| Authors: | Hsu, Ping‐Chih1,2 (AUTHOR), Ko, How‐Wen1,2 (AUTHOR), Chiu, Li‐Chung1,2 (AUTHOR), Huang, Shih‐Hao3 (AUTHOR), Lee, Chung‐Shu2,3 (AUTHOR), Lin, Yu‐Ching2,4,5 (AUTHOR), Kuo, Scott Chih‐Hsi1,2 (AUTHOR), Ju, Jia‐Shiuan1 (AUTHOR), Wang, Chin‐Chou2,6 (AUTHOR), Yang, Cheng‐Ta1,7,8 (AUTHOR) yang1946@adm.cgmh.org.tw |
| Source: | Cancer Medicine. Mar2026, Vol. 15 Issue 3, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20457634 |
|---|---|
| DOI: | 10.1002/cam4.71659 |
